Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas, Daiichi Move Ahead With Factor Xa Programs

This article was originally published in The Pink Sheet Daily

Executive Summary

Japanese pharmas, each in Phase IIb with their oral Factor Xa inhibitors, are behind J&J/Bayer and Bristol/Pfizer, which have Phase III candidates.

You may also be interested in...



Theravance/Astellas Antibiotic Telavancin “Approvable” At FDA

Complete response to agency will not require additional trials, but may include revising label, re-analysis of data, Theravance CEO says.

FDA Advisory Committee Meeting Planned To Review Atrial Fibrillation Drugs

Safety and efficacy of Cardiome/Astellas’ vernakalant and Solvay’s tedisamil will be debated during the Dec. 11-12 meeting, according to Cardiome.

Daiichi Sankyo U.S. CEO Joe Pieroni: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)

Exec discusses the anti-platelet drug prasugrel that Daiichi is developing with Lilly, Daiichi’s planned sales force expansion, and his views on partnering in the U.S. and Asia.

Related Content

Topics

UsernamePublicRestriction

Register

PS065460

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel